Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 21 - 30 of about 176   

Articles published

GSK 1,469.50 -12.00 (-0.81%)
price chart
Heavy Volume And Pre-Market Movement For GlaxoSmithKline (GSK)
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide.
GlaxoSmithKline plc Receives Average Rating of �Hold� from Brokerages (NYSE ...
GlaxoSmithKline plc logo GlaxoSmithKline plc (NYSE:GSK) has earned an average rating of �Hold� from the seventeen analysts that are currently covering the stock, AmericanBankingNews.
Related articles »  
How Strong Are GlaxoSmithKline plc's Dividends?
GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has been steadily lifting its dividend year-on-year, offering yields of around 5% - there's 5.1% pencilled in for this year, on a share price of 1,568p.
Related articles »  
GlaxoSmithKline plc (GSK) Announces Quarterly Results
GlaxoSmithKline plc logo GlaxoSmithKline plc (NYSE:GSK) released its earnings data on Wednesday. The company reported $0.65 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.71 by $0.06, Analyst Ratings Network.
GlaxoSmithKline plc's �Market Perform� Rating Reaffirmed at Sanford C ...
GlaxoSmithKline plc logo GlaxoSmithKline plc (LON:GSK)'s stock had its �market perform� rating reiterated by investment analysts at Sanford C. Bernstein in a note issued to investors on Tuesday.
GlaxoSmithKline plc Price Target Cut to GBX 1460 by Analysts at Jefferies ...  Ticker Report
Related articles »  
GlaxoSmithKline plc Stock Rating Reaffirmed by Panmure Gordon (GSK)
Shares of GlaxoSmithKline plc (NYSE:GSK) traded up 1.21% during mid-day trading on Friday, hitting $53.72. 1,973,737 shares of the company's stock traded hands.
2 Dividend Champions Trading At Rock-Bottom Levels: HSBC Holdings plc And ...
As the FTSE 100 bounces around all-time highs, it's becoming difficult for investors to find attractively priced shares. However, two of the FTSE 100′s largest constituents, HSBC (LSE: HSBA) (NYSE: HSBC.
GSK Signs Licensing Deal With Codexis To Acquire Enzyme Technology
Codexis, Inc. (CDXS) announced after hours yesterday that it has signed an agreement with GlaxoSmithKline plc (GSK) that allows the latter to use its exclusive Code-Evolver� protein engineering platform technology.
GlaxoSmithKline PLC gets technology license from Codexis Inc. for $25M  Gant Daily
GlaxoSmithKline in licensing deal with enzyme-producer Codexis
Related articles »  
Director Deals - GlaxoSmithKline PLC (GSK)
Director Deals - GlaxoSmithKline PLC (GSK). 14 July 2014 | 17:40pm. - Andrew Witty, Chief Executive Officer, has re-invested 1,790 shares in the company on the 10th July 2014 at a price of 1556.00p.
Related articles »  
GlaxoSmithKline plc Stock Rating Reaffirmed by Deutsche Bank (GSK)
GlaxoSmithKline plc (NYSE:GSK) traded up 0.41% during mid-day trading on Wednesday, hitting $54.52. 1,108,463 shares of the company's stock traded hands.
Computershare Limited Rating Reiterated by Deutsche Bank (CPU)  Ticker Report
Related articles »